

A Neoprzewaquinone Analogue from *Salvia miltiorrhiza* Bunge

Jie Yan ^{#1, 2, 3}, Wenxiu Guo ^{#2}, Lanyu Zhou ², Zhixing Cao ^{1, 2},
Jin Pei ^{1, 2}, Yun Deng ^{1, 2}, Bo Li ³, Ding Liu ³, Dale Guo ^{*1, 2}
and Cheng Peng ^{*1, 2}

¹ State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of
Traditional Chinese Medicine, Chengdu 611137, China

² College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

³ Chengdu Push Biotechnology Co., Ltd, Chengdu 610000, China

(Received November 08, 2022; Revised February 22, 2022; Accepted March 15, 2022)

Abstract: (3R,3'R)-2,2',3,3'-tetrahydroneoprzewaquinone A (**1**), a previously undescribed neoprzewaquinone analogue, was isolated from the root of *Salvia miltiorrhiza* Bunge. Its absolute configuration was elucidated by comprehensive analyses of spectra including NMR and MS combined with ECD calculations. MTT assay indicated that **1** can inhibit the proliferation of MV-4-11, TMD-8, MOLM-13, and H460 cell lines with IC₅₀ values of 2.21 μM, 2.48 μM, 3.39 μM, and 2.02 μM respectively.

Keywords: *Salvia miltiorrhiza* Bunge; (3R,3'R)-2,2',3,3'-tetrahydroneoprzewaquinone A; cytotoxic activity. © 2022 ACG Publications. All rights reserved.

1. Introduction

The dry root and rhizome of *Salvia miltiorrhiza* Bunge (Labiatae), also known as red sage or danshen, is a popular traditional Chinese medicine (TCM), which is used for cardiovascular disease, liver cirrhosis, nephrotic syndrome, and pneumonia [1-3]. The compounds tanshinone, propanoic acid, salvianolic acid, flavonoids, and polysaccharides are mainly accountable for the therapeutic effects [4-5]. For example, tanshinone I showed obvious anti-inflammatory effects [6], and tanshinone IIA can resist atherosclerosis [7] and anti-tumor [8-11].

Many undescribed compounds have been found of *S. miltiorrhiza* in recent years, such as neoprzewaquinone A, 3-hydroxy-2-(2'-formyloxy-1'-methylethyl)-8-methyl-1,4-phenanthrenedione, and

* Corresponding authors: E-mail: Guodale@cdutcm.edu.cn (Dale Guo); E-mail: pengcheng@cdutcm.edu.cn (Chen Peng).

Jie Yan and Wenxiu Guo contributed equally to this work.

A neoprzewaquinone analogue from *Salvia miltiorrhiza*

(8'R)-isosalvianolic acid C methyl ester [12,13], etc. As a part of our work to search for more bio-active compounds with novel structure from TCM, *S. miltiorrhiza* was selected. After a systematic phytochemical investigation, a previously undescribed compound tetrahydroneoprzewaquinone A (**1**) has been found (see Figure 1). Herein, we reported the isolation, structural elucidation, and cytotoxicity.

2. Materials and Methods

2.1. Instruments and Materials

The semi-preparative HPLC (Waters, USA) was conducted by using an Ultimate XB-C₁₈ column (4.6×250 mm, 5 μm) (Welch Technology Co., Ltd, China). The 1D and 2D NMR data were obtained using a Bruker Bruker-Ascend-600-MHz spectrometer (Bruker Corporation, Billerica, MA, USA). HR-ESI-MS was measured on a Q Exactive UHMR Hybrid Quadrupole-Orbitrap 16 mass spectrometer (Thermo Fisher Scientific, MA, USA). Different types of cancer cells were cultured in an MCO-15AC CO₂ incubator (Sanyo Semiconductor, Japan), MCV-13161FT clean bench (Sanyo Semiconductor, Japan). The MKG9823 inverted microscope (Carl Zeiss AG, German) and Cell counting plate (Shanghai Qiujiing Biochemical Reagent Instrument Co., Ltd, China) were used to observe and count the cells, and the OD value was measured with a MK 3 automatic microplate reader (Thermo Fisher, USA). HepG-2 (Human liver cancer cell), HeLa (Human cervical cancer cell), H460 (Human large cell lung cancer cell), TMD-8 (Human diffuse large B lymphoma cells), MOLM-13 (Human acute myeloid leukemia cell), and MV-4-11 (Human myeloid monocytic leukemia cells) were purchased from the American type culture collection.

2.2. Separation and Purification

After crushing and blending the dried *S. miltiorrhiza*, the powder was extracted 3 times with 80~90% ethanol under reflux for 1 hour each time (the weight of ethanol is 8~10 times of medicinal powder) [14, 15]. Then recovered the solvent to no alcohol smell and the concentrated extract was obtained. Adding 6-10 times of water to disperse evenly, the obtained aqueous dispersion was separated by using AB-8 macroporous adsorption resin column chromatography (methanol/water, v/v = 80:20 as the mobile phase) [16]. Collect the chromatographic solution containing diterpene quinones, and then concentrate it until no alcohol smell to obtain a concentrated solution by reduced pressure. Filter the concentrated solution, and then the filtrate was prepared and separated by C₁₈ reverse phase chromatography packing (acetonitrile/water, v/v = 62:38 as the mobile phase, detection wavelength 270nm).

2.3. Cytotoxicity Test

The inhibitory effects of compound **1** on MV-4-11, TMD-8, MOLM-13, H460, HeLa, and HepG-2 cells were determined by the MTT method with the positive control Cisplatin [17-21]. The cells in the logarithmic growth phase were added to the complete medium to make a cell suspension with a concentration of 2×10⁴ cells/mL, and 100 μL complete medium was added per well containing 0.63, 1.25, 2.50, 5.00, 10.00, and 20.00 μg/mL of compound **1**. Set the cells containing 0.1% DMSO complete medium as the solvent control group, and 3 multiple wells for each drug concentration. After 72h incubate them at 37°C and 5% CO₂, 20 μL of 5mg/mL MTT solution was added to each well. After incubating for another 2~4h, then add 80 μL of 20% SDS to each well and incubate overnight. On the next day, using a microplate reader to determine the absorbance at 570nm (optical density, OD). Calculate the cell inhibition rate according to the following formula: cell inhibition rate = (control group OD value-experimental group OD value)/control group OD value×100%. The biostatistical software Graphpad Prism was used to fit the growth inhibition curves of the drugs on different cells, and the half-maximal inhibitory concentration (IC₅₀) value was calculated.

2.4. Spectroscopic Data

Tetrahydroneoprzewaquinone A (**1**): Red solid powder; $[\alpha]_D^{20} = -56.25$ (c 0.02, MeOH); UV (MeOH): $\lambda_{\max} = 219$ (4.64) and 276 (4.78) nm; IR (KBr) $\nu_{\max}$: 3017, 2966, 2879, 1747, 1689, 1617, 1555, 1480,

1372, 1299, 1027 cm^{-1} ; ^1H -NMR and ^{13}C -NMR (600/150 MHz, CD_3OD) see Table 1; HR-ESI-MS calcd. for $\text{C}_{36}\text{H}_{32}\text{O}_6\text{Na}$ $[\text{M}+\text{Na}]^+$ m/z : 583.2092, found m/z : 583.2090.




Figure 1. Chemical structure of compound **1**

Table 1. ^1H (600 MHz) and ^{13}C NMR (150 MHz) data of compound **1** (δ in ppm, J in Hz) in CD_3OD

Position	δ_{H}	δ_{C}	Position	δ_{H}	δ_{C}
2/2'	4.95 (2H, td, 9.5, 3.5) 4.42 (2H, m)	81.8	18	3.31 (2H, dd, 8.1, 2.3)	24.4
3/3'	3.55 (2H, m)	34.4	19		143.1
4/4'		118.4	20	2.50 (2H, m)	31.7
5		175.9	21	1.85 (2H, quin, 6.4)	23.1
6		184.3	22	3.23 (2H, t, 6.4)	29.0
7		128.2	23	5.59 (1H, s) 5.11 (1H, s)	110.7
8		143.4	24	2.05 (3H, s)	18.5
9		140.8	5'		175.4
10	7.50 (1H, d, 8.4)	127.5	6'		183.6
11	7.55 (1H, d, 7.9)	123.4	7'		127.4
12		126.0	8'		143.3
13		171.9	9'		140.5
14/14'	1.32 (6H, d, 6.9)	17.4	10'	7.96 (1H, d, 8.1)	130.0
15		131.2	11'	7.52 (1H, d, 8.1)	122.6
16	6.12 (1H, s)	129.3	12'		127.7
17	2.22 (2H, m)	22.0	13'		171.6




Figure 2. Key HMBC (arrows) and ^1H - ^1H COSY (bold) correlations of **1**




Figure 3. Calculated ECD curve and experimental ECD spectrum of **1**

3. Results and Discussion

3.1. Structure Elucidation

Compound **1** was obtained as a red solid powder. Its molecular formula was assigned as HR-ESI-MS by the pseudo-molecular ion peak at m/z 583.2090 $[M+Na]^+$ (calculated for 583.2092, $C_{36}H_{32}O_6Na^+$). The 1H -NMR spectrum indicated the presence of three methyl protons at δ 1.32 (6H, d, J = 6.9 Hz, H-14/H14') and δ 2.05 (3H, s, H-24), seven methylene protons at δ 4.95 (2H, td, J = 9.5, 3.5 Hz, H-2/H-2'), 4.42 (2H, ddd, J = 8.7, 6.2, 2.3 Hz, H-2/H-2'), 3.31 (2H, dd, J = 8.1, 2.3 Hz, H-18), 3.23 (2H, t, J = 6.4 Hz, H-22), 2.50 (2H, m, H-20), 2.22 (2H, m, H-17), 1.85 (2H, quin, J = 6.4 Hz, H-21), and seven double bond proton at δ 7.96 (1H, d, J = 8.1 Hz, H-10'), 7.55 (1H, d, J = 7.9 Hz, H-11), 7.52 (1H, s, H-11'), 7.50 (1H, d, J = 8.4 Hz, H-10), 6.12 (1H, m, H-16), 5.59 (1H, s, H-23), 5.11 (1H, s, H-23). The ^{13}C -NMR spectrum of **1** indicated the presence of four carbonyl carbon signals at δ_C 184.3 (C-6), 183.6 (C-6'), 175.9 (C-5), 175.4 (C-5'), and twenty olefinic and aromatic carbon signals at δ_C 171.9 (C-13), 171.6 (C-13'), 143.4 (C-8), 143.3 (C-8'), 143.1 (C-19), 140.8 (C-9), 140.5 (C-9'), 131.2 (C-15), 130.0 (C-10'), 129.3 (C-16), 128.2 (C-7), 127.7 (C-12'), 127.5 (C-10), 127.4 (C-7'), 126.0 (C-12), 123.4 (C-11), 122.6 (C-11'), 118.4 (C-4'), 110.7 (C-23). (see Table 1)

The 1H -NMR spectra of **1** are similar to neo-przewaquinone A [12, 22], expecting the absence of two olefinic protons, and the presence of two more methylene and two methine signals. The HMBC correlations from H-14/H14' to C-2/2', C-3/C-3', C-4/4' indicates methylene and methane replayed the olefinic carbons at C2/2' and C3/3'. The 1H - 1H COSY correlations of H-18/H-17/H-16/H-15/H-24, of H-10'/H-11', and H-22/H-21/H-20 as well as the HMBC correlations of H-24/C-16, C-15, C-9, of H-22/C-20, C-19, C-9', of H-20/C-9' and H-22/C-9, C-8, C-7 generated the planar structure of **1** as shown in Figure 2. The weak NOESY correlations of H-24/H-17 indicated the E configuration of the double bond between C-15 and C-16. The absolute configuration of the chiral carbons at the positions of C-3 and C-

3' were deduced as *R* by subsequent ECD calculations [23] shown in Figure 3. Thus, compound **1** was finally elucidated as (3*R*,3'*R*)-2,2',3,3'-tetrahydroneoprzewaquinone A.

3.2. Cell Viability Assay

MTT test indicated that compound **1** showed obvious inhibitory activity against MV4-11, TMD-8, MOLM-13, and H460 cells with IC₅₀ values of 2.21 μ M, 2.48 μ M, 3.39 μ M, and 2.02 μ M, respectively (The IC₅₀ value of each cell line is shown in Table 2 and Figure 4). The compound **1** is sensitive to MV4-11, TMD-8, MOLM-13, and H460 cells, but insensitive to HeLa and HepG-2 cells, which may have a certain potential targeting effect and worth further study.

Table 2. The results of the measurement of IC₅₀ of Compound **1** and Cisplatin on different cells

Cell line	Cell type	Compd. 1 IC ₅₀ (μ M)	Cisplatin IC ₅₀ (μ M)
MV-4-11	Human acute myeloid leukemia cells	2.21	8.23
TMD-8	Human diffuse large B lymphoma cells	2.48	ND
Molm-13	Human acute myeloid leukemia cells	3.39	17.27
H460	Human lung cancer cell	2.02	9.36
HeLa	Human cervical cancer cells	>35.70	18.43
HepG-2	Human hepatoma cells	>35.70	5.78




Figure 4. Growth inhibition curves of **1** on MV4-11, TMD-8, MOLM-13, H460, HepG-2, and HeLa cells (72 hours)

Acknowledgments

The work was supported by the China Postdoctoral Science Foundation (2020M673566XB); The Application Basic Research Project of the Science and Technology Department of Sichuan Province (2019YJ0333); National Natural Science Foundation of China (81503200); Special Scientific and Technological Research Project of Sichuan Province Administration of Traditional Chinese Medicine (2018QN013)

Supporting Information

Supporting Information accompanies this paper on <http://www.acgpubs.org/journal/records-of-natural-products>

ORCID

Jie Yan: [0000-0002-9694-8722](https://orcid.org/0000-0002-9694-8722)

Wenxiu Guo: [0000-0001-6511-4656](https://orcid.org/0000-0001-6511-4656)

Lanyu Zhou: [0000-0002-2863-625X](https://orcid.org/0000-0002-2863-625X)

Zhixing Cao: [0000-0001-6776-613X](https://orcid.org/0000-0001-6776-613X)

Jin Pei: [0000-0002-1695-2538](https://orcid.org/0000-0002-1695-2538)

Yun Deng: [0000-0002-3428-8992](https://orcid.org/0000-0002-3428-8992)

Bo Li: [0000-0002-2263-2231](https://orcid.org/0000-0002-2263-2231)

Ding Liu: [0000-0002-1345-2693](https://orcid.org/0000-0002-1345-2693)

Dale Guo: [0000-0003-3219-7066](https://orcid.org/0000-0003-3219-7066)

Peng Cheng: [0000-0003-3303-906X](https://orcid.org/0000-0003-3303-906X)

References

- [1] B. Gao (2018). Analysis of pharmacological effects and clinical application of Danshen, *Chin. J. Mod. Drug. Appl.* **12**, 196-197.
- [2] Y. Feng (2017). Modern pharmacological study and clinical application of radix *salvia miltiorrhiza*, *Clin. J. Chin. Med.* **9**, 46-47.
- [3] Y. Xu, T. Chen and M. Chen (2021). Research progress of chemical constituents and pharmacological effects of *Salvia miltiorrhiza* Bunge, *Strait Pharm. J.* **33**, 45-48.
- [4] Y. Li, Z. C. Zhao, S. Q. Lin and Z. L. Huang (2021). Research progress of main chemical components and extraction and separation methods of *Salvia miltiorrhiza* Bunge, *Acta. Chin. Med. Pharm.* **49**, 106-111.
- [5] A. L. Sun, Y. Q. Zhang, A. F. Li, Z. L. Meng and R. M. Liu (2011). Extraction and preparative purification of tanshinones from *Salvia miltiorrhiza* Bunge by high-speed counter-current chromatography, *J. Chromatogr. B.* **879**, 1899-1904.
- [6] S. L. Ma, D. W. Zhang, H. X. Lou, L. R. Sun and J. B. Ji (2016). Evaluation of the anti-inflammatory activities of tanshinones isolated from *Salvia miltiorrhiza* var. *alba* roots in THP-1 macrophages, *J. Ethnopharmacol.* **188**, 193-199.
- [7] S. Gao, Z. P. Liu, H. Li, P. J. Little, P. Q. Liu and S. W. Xu (2012). Cardiovascular actions and therapeutic potential of tanshinone IIA, *Atherosclerosis* **220**, 3-10.
- [8] L.L. Zhou, W. K. Chan, N. H. Xu, K. Xiao, H. W. Luo, K. Q. Luo and D. C. Chang (2008). Tanshinone IIA, an isolated compound from *Salvia miltiorrhiza* Bunge, induces apoptosis in HeLa cells through mitotic arrest, *Life Sci.* **83**, 394-403.
- [9] Z. C. Zhang, J. Gao, Y. Y. Wang, T. Song, J. Zhang, G. Y. Wu, T. T. Zhang and G. H. Du (2009). Tanshinone IIA triggers p53 responses and apoptosis by RNA polymerase II upon DNA minor groove binding, *Bio. Pharm.* **78**, 116-1322.
- [10] S. H. Won, H. J. Lee, S. J. Jeong, J. X. Lü and S. H. Kim (2012). Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells, *Phytother. Res.* **26**, 669-674.
- [11] T. L. Chiu and C. C. Su (2010) Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential, *Int. J. Mol. Med.* **25**, 231-236.
- [12] C. Zhang, Y. L. Yi, K. Hao, G. L. Liu and G. X. Wang (2013). Algicidal activity of *Salvia miltiorrhiza* Bunge on *Microcystis aeruginosa*-Towards identification of algicidal substance and determination of inhibition mechanism, *Chemosphere* **93**, 997-1004.
- [13] H. Y. Ma, H. Y. Gao, L. Sun, J. Huang, X. M. Xu and L. J. Wu (2011). Constituents with α -glucosidase and advanced glycation end-product formation inhibitory activities from *Salvia miltiorrhiza* Bge, *J. Nat. Med.* **65**, 37-42.
- [14] L. Q. Hung, P. T. Thuong and N. H. Tung (2019). A new ursane-type triterpene from the roots of *Salvia miltiorrhiza* Bunge, *Rec. Nat. Prod.* **13**, 429-433.
- [15] Y. C. Wang, A. L. Sun, A. F. Li, X. X. Qin and R. M. Liu (2016). Method for separating and purifying tanshinone monomer components from *Salvia miltiorrhiza*: China, CN105906687A[P]. 2016-08-31.

- [16] Y. Chen, W. J. Zhang, T. Zhao, F. Li, M. Zhang, J. Li, Y. Zou, W. Wang, S. J. Cobbina, X. Y. Wu and L. Q. Yang (2016). Adsorption properties of macroporous adsorbent resins for separation of anthocyanins from mulberry, *Food Chem.* **194**, 712-722.
- [17] R. S. Compagnone, K. Chavez, E. Mateu, G. Orsini, F. Arvelo and A. I. Suárez (2010). Composition and cytotoxic activity of essential oils from *Croton matourensis* and *Croton micans* from Venezuela, *Rec. Nat. Prod.* **4**, 101-108.
- [18] U. Amna, Halimatussakdiah, P. Wahyuningsih, N. Saidi and R. Nasution (2019). Evaluation of cytotoxic activity from Temurui (*Murraya koenigii* [Linn.] Spreng) leaf extracts against HeLa cell line using MTT assay, *J. Adv. Pharm. Technol. Res.* **10**, 51-55.
- [19] G. Renda, U. Özgen, Z. Ünal, S. Sabuncuoğlu, E. Palaska and İ. E. Orhan (2017). Flavonoid derivatives from the aerial parts of *Trifolium trichocephalum* M. Bieb. and their antioxidant and cytotoxic activity, *Rec. Nat. Prod.* **11**, 479-484.
- [20] O. Keta , M. Deljanin, V. Petkovic, G. Zdunić, T. Janković, J. Živković , A. Ristic Fira , I. Petrović and K. Šavikin (2021). Pomegranate (*Punica granatum* L.) peel extract: potential cytotoxic agent against different cancer cell Lines, *Rec. Nat. Prod.* **14(5)**, 326-329.
- [21] P. Kumboonma, T. Senawong, S. Saenglee and C. Phaosiri (2021) Discovery of new capsaicin and dihydrocapsaicin derivatives as histone deacetylase inhibitors and molecular docking studies, *Org. Commun.* **14(2)**, 133-143.
- [22] W. S. Chen, X. M. Jia, W. D. Zhang, Z. Y. Lou and C. Z. Qiao (2003). Chemical constituents in the roots of *Salvia przewalskii* Maxim, *Acta Pharm. Sin.* **38**, 354-357.
- [23] F. Ju, Q.X. Kuang, Q.Z. Li, L.J. Huang, W.X. Guo, L.Q. Gong, Y.F. Dai, L. Wang, Y.C. Gu, D. Wang, Y. Deng, D.L. Guo (2021). Aureonitol analogues and orsellinic acid esters isolated from *Chaetomium elatum* and their antineuroinflammatory activity, *J. Nat. Prod.* **84**, 3044-3054.

A C G
publications

© 2022 ACG Publications